Evaluating the Preliminary Efficacy and Safety of JS207 in NSCLC After Progression Following Platinum-based Chemotherapy and Immunotherapy

Record History

See every version on ClinicalTrials.gov ↗

1. Stopped Sep 22, 2026 Trial terminated Sponsor's reason: The research and development strategy was adjusted, so the research was suspended Show 4 more changesShow less

   • Final enrollment: 18 participants (planned 66)
   • Primary and study completion dates changed from estimate of Jun 26, 2026 to Jul 9, 2026
   • Eligibility criteria expanded, about 6 words
   • Site details revised at 18 of 18 sites
2. Minor Feb 4, 2026 Secondary endpoints: details revised at 1 of 6 entriesv6
3. Minor Dec 25, 2025 Study sites: 26 to 18

   • Eligibility criteria shortened, about 120 words

   v5
4. Notable Sep 24, 2025 Trial status: Not Yet Recruiting to Recruiting

   • Enrollment target: 72 to 66
   • Study sites: 18 to 26

   v4
5. Notable Jul 10, 2025 Enrollment target: 42 to 72v3 Show 5 more changesShow less

   • Start date: May 15, 2025 to Jul 15, 2025
   • Study sites: 12 to 18
   • Primary and study completion dates: Sep 26, 2026 to Jun 26, 2026
   • Interventions: JS207 injection (Drug) to JS207 injection (Drug), JS207 injection +JS004 injection (Drug), JS207 injection +docetaxel (Drug)
   • Study arms: 1 to 3
6. Minor Apr 26, 2025 Re-verified, no change to tracked fieldsv2
7. Minor Apr 6, 2025 Study First Submitted

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.